AXIM Biotechnologies, Inc., a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, has engaged 624 Advisors, owned and managed by Dr. Alan J. Touch, as Chief Medical & Regulatory Affairs Advisor. This strategic appointment provides AXIM with enhanced technical continuity, regulatory depth, and strategic execution capability at a pivotal stage of the company's development.
Dr. Touch brings more than three decades of global leadership across diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of the first ocular diagnostic technologies acquired by AXIM and the inventor of the world's first colored contact lens. His extensive background includes former leadership roles at Bausch & Lomb and as Principal Strategist for Ophthalmology, Medical Devices and Diagnostics at INC Research (Syneos Health). As Chief Science Officer of an ophthalmic CDMO, he led the development of several proprietary dry eye disease products, including the first eye drop based on addressing the Inflammatory Cascade through a novel pathway.
The importance of this appointment lies in Dr. Touch's unique combination of inventor-level knowledge of AXIM's technology with significant senior-level experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. His involvement strengthens AXIM's regulatory strategy, quality foundation, and clinical execution while positioning the company for efficient global expansion and long-term operational scale. This comes at a critical time as AXIM advances toward key regulatory and commercial milestones, including upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure.
Catalina Valencia, President and CEO of AXIM Biotechnologies, emphasized the strategic value of this engagement, stating that Dr. Touch's advisory role is designed to provide highly qualified support across these critical areas. The company is building a strong foundation for market-sensitive regulatory excellence and clinical credibility for its products, particularly the TearScan® platform that enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings.
Dr. Touch's background uniquely aligns with AXIM's current efforts and upcoming goals, including his inventor-level understanding of lactoferrin and immunoassay diagnostics, deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks, and proven leadership in regulatory affairs, quality systems, clinical development, and manufacturing scale-up. This engagement is expected to reduce reliance on external consultants and accelerate readiness for commercialization and global growth.
For more information about AXIM Biotechnologies and its diagnostic technologies, visit https://www.aximbiotech.com. The original press release announcing this appointment can be viewed at https://www.newmediawire.com.
This development matters because it represents a strategic strengthening of AXIM's regulatory and clinical capabilities at a crucial juncture in the company's growth. With increasing regulatory complexity in the medical device and diagnostic sectors, particularly for ocular health products, having a preeminent regulatory specialist with direct knowledge of the company's technology provides a significant competitive advantage. The implications extend to potentially faster regulatory approvals, more efficient global market expansion, and enhanced credibility with healthcare providers and regulatory agencies worldwide.
